Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug

Roche has agreed to pay $190 million upfront to license a non-incretin obesity treatment from South Korea's Hanmi Pharm, with milestone payments potentially reaching $2.3 billion. The deal extends Roche's recent pattern of acquiring obesity-related assets through partnerships. The candidate is still in early-stage development and aims to preserve muscle mass while promoting weight loss.